###begin article-title 0
###xml 49 54 49 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling
###end article-title 0
###begin p 1
Conceived and designed the experiments: TH DJW PWL. Performed the experiments: TH MK. Analyzed the data: TH. Contributed reagents/materials/analysis tools: JY VLW BL PWL. Wrote the paper: TH. Provided input on statistical analyses: FP. Provided experimental advice and discussion regarding data interpretation: MC.
###end p 1
###begin p 2
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 246 251 246 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 322 327 322 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 451 456 451 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 656 661 656 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 715 720 715 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 743 747 743 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 959 964 959 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1137 1142 1137 1142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1347 1351 1347 1351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP3</italic>
###xml 1356 1360 1356 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP6</italic>
###xml 1378 1383 1378 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHA3</italic>
###xml 1385 1388 1385 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIT</italic>
###xml 1394 1398 1394 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT1</italic>
###xml 1431 1434 1431 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMO</italic>
###xml 1523 1529 1523 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1567 1572 1567 1572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1649 1655 1649 1655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1733 1738 1733 1738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1784 1790 1784 1790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1872 1877 1872 1877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
A CpG island methylator phenotype (CIMP) is displayed by a distinct subset of colorectal cancers with a high frequency of DNA hypermethylation in a specific group of CpG islands. Recent studies have shown that an activating mutation of BRAF (BRAFV600E) is tightly associated with CIMP, raising the question of whether BRAFV600E plays a causal role in the development of CIMP or whether CIMP provides a favorable environment for the acquisition of BRAFV600E. We employed Illumina GoldenGate DNA methylation technology, which interrogates 1,505 CpG sites in 807 different genes, to further study this association. We first examined whether expression of BRAFV600E causes DNA hypermethylation by stably expressing BRAFV600E in the CIMP-negative, BRAF wild-type COLO 320DM colorectal cancer cell line. We determined 100 CIMP-associated CpG sites and examined changes in DNA methylation in eight stably transfected clones over multiple passages. We found that BRAFV600E is not sufficient to induce CIMP in our system. Secondly, considering the alternative possibility, we identified genes whose DNA hypermethylation was closely linked to BRAFV600E and CIMP in 235 primary colorectal tumors. Interestingly, genes that showed the most significant link include those that mediate various signaling pathways implicated in colorectal tumorigenesis, such as BMP3 and BMP6 (BMP signaling), EPHA3, KIT, and FLT1 (receptor tyrosine kinases) and SMO (Hedgehog signaling). Furthermore, we identified CIMP-dependent DNA hypermethylation of IGFBP7, which has been shown to mediate BRAFV600E-induced cellular senescence and apoptosis. Promoter DNA hypermethylation of IGFBP7 was associated with silencing of the gene. CIMP-specific inactivation of BRAFV600E-induced senescence and apoptosis pathways by IGFBP7 DNA hypermethylation might create a favorable context for the acquisition of BRAFV600E in CIMP+ colorectal cancer. Our data will be useful for future investigations toward understanding CIMP in colorectal cancer and gaining insights into the role of aberrant DNA hypermethylation in colorectal tumorigenesis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 271 274 271 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Jones1">[1]</xref>
###xml 487 490 487 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Toyota1">[2]</xref>
###xml 492 495 492 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Issa1">[3]</xref>
###xml 542 545 542 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Yamashita1">[4]</xref>
###xml 645 648 645 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 315 320 <span type="species:ncbi:9606">human</span>
Aberrant DNA methylation at CpG islands has been widely observed in cancer. Promoter CpG island hypermethylation associated with inactivation of selected tumor suppressor genes appears to be critical in tumors from inception through to maintenance of the tumor phenotype [1]. Distinct subgroups of several types of human cancers have been proposed to have a CpG island methylator phenotype (CIMP) in which an exceptionally high frequency of cancer-specific DNA hypermethylation is found [2], [3]. Although this concept has been controversial [4], we have confirmed the existence of CIMP in colorectal cancer in a large-scale comprehensive study [5].
###end p 4
###begin p 5
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-OBrien1">[6]</xref>
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 191 194 191 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Samowitz1">[7]</xref>
###xml 339 342 339 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Issa1">[3]</xref>
###xml 344 347 344 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 349 352 349 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Samowitz1">[7]</xref>
###xml 354 357 354 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Kambara1">[8]</xref>
###xml 537 541 537 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 563 566 563 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 678 683 678 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 685 688 685 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 704 708 704 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 871 874 871 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Minoo1">[9]</xref>
###xml 879 883 879 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 917 921 917 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Rosenberg1">[10]</xref>
###xml 822 830 <span type="species:ncbi:9606">patients</span>
CIMP in colorectal cancer may arise through a distinct pathway originating in certain subtypes of serrated polyps [6] and is observed in approximately 15% of all colorectal cancer cases [5], [7]. Features associated with CIMP in colorectal cancer include gender (female), proximal location, and poorly differentiated or mucinous histology [3], [5], [7], [8]. Our study using a newly developed CIMP marker panel in colorectal cancers demonstrated that sporadic microsatellite instability (MSI+) occurs as a consequence of CIMP-associated MLH1 DNA hypermethylation [5]. Furthermore, we found a strong association of CIMP with the presence of an activated mutant form of BRAF (BRAFV600E) [5]. Both CIMP and BRAF mutations have been reported in the earliest stages of colorectal neoplasia: CIMP in apparently normal mucosa of patients predisposed to multiple serrated polyps [9] and BRAF mutations in aberrant crypt foci [10].
###end p 5
###begin p 6
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Oliveira1">[11]</xref>
###xml 171 175 171 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 265 270 265 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 320 324 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 335 339 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Garnett1">[12]</xref>
###xml 354 358 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 363 367 351 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 458 462 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Davies1">[13]</xref>
###xml 598 602 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Rosenberg1">[10]</xref>
###xml 604 608 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Haigis1">[14]</xref>
The RAS-RAF-MEK-ERK signaling pathway is frequently hyperactivated in colorectal cancer. KRAS mutations occur most frequently in 30-40% of all colorectal cancers [11] and BRAF mutations are present at a frequency of 5-22%, in which the constitutively activated BRAFV600E variant accounts for approximately90% of all the BRAF mutations [12]. Mutations in KRAS and BRAF are generally mutually exclusive, implying equivalent downstream effects in tumorigenesis [13]. However, recent studies have indicated that mutations of these genes might play distinct roles in tumor initiation and/or maintenance [10], [14].
###end p 6
###begin p 7
###xml 44 49 44 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 94 99 94 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 256 261 256 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 358 363 358 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 647 651 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Bibikova1">[15]</xref>
###xml 652 656 652 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Katari1">[24]</xref>
###xml 815 819 815 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Bibikova1">[15]</xref>
###xml 820 824 820 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-LaddAcosta1">[17]</xref>
###xml 826 830 826 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Byun1">[22]</xref>
###xml 832 836 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Christensen1">[23]</xref>
###xml 979 984 979 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1111 1116 1111 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1242 1247 1242 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
The extremely tight association between BRAFV600E and CIMP raises the question of whether BRAFV600E plays a causal role in the development of CIMP or whether CIMP-associated promoter hypermethylation provides a favorable setting for the acquisition of BRAFV600E. In this study, we searched for possible molecular explanations for the association between BRAFV600E and CIMP using the Illumina GoldenGate DNA methylation platform, which examines the DNA methylation status of 1,505 CpG sites located at 807 genes. The GoldenGate DNA methylation assay has been widely used in various studies and is now a standard method for DNA methylation analysis [15]-[24]. Findings obtained from the commercially available "GoldenGate Methylation Cancer Panel I", in particular, have been validated using various other techniques [15]-[17], [22], [23], making it a reliable source for DNA methylation measurements across 1,505 loci. We were not able to demonstrate a causal contribution of BRAFV600E to CIMP in our cell culture system. However, we identified genes whose DNA hypermethylation was significantly linked with BRAFV600E in primary colorectal tumors. Inactivation of these specific genes in the context of CIMP might drive the acquisition of BRAFV600E in CIMP+ colorectal tumors.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 23 28 <span type="species:ncbi:9606">Human</span>
Characterization of 21 Human Colorectal Cancer Cell Lines
###end title 9
###begin p 10
###xml 55 60 55 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 135 143 135 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 469 474 469 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 588 592 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 597 601 597 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 619 627 619 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g001">Figure 1</xref>
###xml 756 759 756 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 950 958 948 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g001">Figure 1</xref>
###xml 1008 1012 1006 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1017 1021 1015 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1285 1290 1283 1288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
We first sought to determine whether expression of BRAFV600E would induce DNA hypermethylation at CpG sites associated with CIMP in an in vitro cell culture system. Since primary colonic epithelial cells were not readily available, we screened for colorectal cancer cell lines that do not have substantial DNA methylation at CIMP-defining loci and carry wild-type forms of both BRAF and KRAS. Such cell lines would serve as suitable systems for the introduction of BRAFV600E. We selected 21 colorectal cancer cell lines, characterized their DNA methylation profiles, and determined their BRAF and KRAS mutation status (Figure 1). We used MethyLight to assess the DNA methylation status of five CIMP-defining markers previously identified in our laboratory [5]. Using a PMR (percent of methylated reference) of >/=10 as a threshold for positive methylation, we identified six cell lines that lacked DNA methylation for all five CIMP-specific markers (Figure 1). To test our hypothesis, we initially chose the BRAF and KRAS wild-type Caco-2 and COLO 320DM cell lines for their ease in culturing and transfection. However, the study described below is limited to COLO 320DM cells, since we were not able to isolate any stably transfected Caco-2 clones that showed detectable level of BRAFV600E expression (data not shown).
###end p 10
###begin title 11
Characteristics of 21 colorectal cancer cell lines.
###end title 11
###begin p 12
###xml 454 458 450 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 471 475 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
MethyLight was used to assess the DNA methylation status of five CIMP-defining markers. A PMR of >/=10 was used as a threshold for positive methylation. Black boxes indicate PMR >/=10, and white boxes indicate PMR <10. The DNA methylation frequencies of the five CIMP markers increase from top to bottom. Microsatellite instability status for each cell line is listed as microsatellite stable (MSS) or harboring instability (MSI). The mutation status of BRAF exon 15 and KRAS exon 2 are listed.
###end p 12
###begin title 13
###xml 27 32 27 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Stable Transfection of BRAFV600E in COLO 320DM Cells
###end title 13
###begin p 14
###xml 54 59 54 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 129 134 129 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 212 221 212 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g002">Figure 2A</xref>
###xml 244 249 244 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 351 360 351 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g002">Figure 2A</xref>
###xml 429 434 429 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
We transfected COLO 320DM cells with an HA-tagged BRAFV600E cDNA and isolated G418-resistant clones. The expression level of BRAFV600E was determined by western blotting using an antibody against the HA epitope (Figure 2A). The activity of BRAFV600E was confirmed by examining the activation of ERK1/2 using an antibody against phosphorylated ERK1/2 (Figure 2A). Eight stably transfected clones exhibiting high expression of BRAFV600E, as well as strong activation of ERK1/2, were individually grown in culture, and genomic DNA was isolated at various passages (between 2 and 27) from these clones. Four empty-vector transfected clones (EVCs) were grown in the same conditions and used as controls.
###end p 14
###begin title 15
###xml 17 22 17 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Selection of BRAFV600E stably-transfected clones and their Illumina GoldenGate DNA methylation profiles.
###end title 15
###begin p 16
###xml 22 27 22 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 152 157 152 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 228 233 228 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 412 417 412 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 587 591 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Bibikova2">[16]</xref>
(A) Expression of BRAFV600E and ERK1/2 phosphorylation in stably transfected COLO 320DM cells. Blots were probed with the anti-HA antibodies for HA-BRAFV600E, anti-phospho-ERK1/2, and anti-ERK1. Asterisks indicate the eight BRAFV600E transfected clones that were subjected to DNA methylation analysis at various cell passages. (B) DNA methylation profiles of untransfected COLO 320DM cells, empty vector and BRAFV600E transfected COLO 320DM clones, as determined by the Illumina GoldenGate DNA methylation assay. The DNA methylation data were scored as beta-values as previously defined [16]. Each row corresponds to an individual CpG locus and the data were sorted by average beta-value across all samples. Each clone is ordered from left to right in increasing number of passages. EVC: empty-vector transfected clones.
###end p 16
###begin title 17
###xml 36 41 36 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
DNA Methylation Analysis of the BRAFV600E Transfected COLO 320DM Clones
###end title 17
###begin p 18
###xml 121 126 121 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 215 224 215 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g002">Figure 2B</xref>
###xml 311 316 308 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 361 366 358 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 556 561 553 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 610 619 607 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g002">Figure 2B</xref>
We next determined the DNA methylation status of 1,505 CpG sites located at 807 different genes in each of the eight BRAFV600E clones and four EVCs using the Illumina GoldenGate Methylation Cancer Panel 1 platform (Figure 2B). We found that the DNA methylation beta-values across all 1,505 CpG sites in the BRAFV600E transfected clones (regardless of their BRAFV600E expression level) were very similar to those of empty-vector control clones and relatively stable over time. This suggests that there was no overall increase in DNA hypermethylation in BRAFV600E transfected clones in the CpG targets analyzed (Figure 2B).
###end p 18
###begin p 19
###xml 56 61 56 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 307 317 307 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s001">Dataset S1</xref>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 352 356 352 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 405 408 405 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 410 418 410 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s002">Table S1</xref>
###xml 587 592 584 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 673 685 670 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A, IGF2</italic>
###xml 691 695 688 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 764 772 761 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g003">Figure 3</xref>
###xml 938 939 935 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 997 1018 994 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1029 1037 1026 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s003">Table S2</xref>
###xml 1122 1129 1119 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 1131 1138 1128 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 1144 1149 1141 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 1276 1281 1273 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 1484 1489 1481 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 1527 1532 1524 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 1599 1604 1596 1601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 1615 1618 1612 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 1681 1686 1678 1683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1751 1759 1748 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g003">Figure 3</xref>
###xml 1901 1917 1895 1911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g004">Figure 4A and 4B</xref>
###xml 1984 1989 1978 1983 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 2069 2078 2063 2072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g004">Figure 4B</xref>
###xml 2273 2289 2261 2277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g004">Figure 4C and 4D</xref>
###xml 2434 2439 2422 2427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
We next determined whether the stable expression of BRAFV600E specifically increased the DNA methylation of only CIMP-associated markers in the 1,505 interrogated CpG sites. These sites were determined by screening 58 primary colorectal tumor samples using the Illumina GoldenGate DNA methylation platform (Dataset S1). The mutation status of BRAF and KRAS in these samples had been determined previously [5] (Table S1). Unsupervised two-dimensional cluster analysis of the DNA methylation beta-values revealed a distinct cluster of 11 tumor samples, the majority of which contained BRAFV600E and showed frequent DNA methylation of known CIMP-associated markers, including CDKN2A, IGF2, and MLH1 (data not shown). We defined this subgroup as CIMP-positive tumors (Figure 3). We then identified a total of 100 CpG sites that have significantly higher levels of DNA methylation in CIMP-positive (CIMP+) versus CIMP-negative (CIMP-) tumors (P<0.001 after correction for multiple comparisons, see the Materials and Methods section) (Table S2). It should be noted that reactions for three of the MethyLight-based CIMP markers (CACNA1G, NEUROG1, and SOCS1) previously identified in our laboratory are not included in the Illumina GoldenGate Methylation Cancer Panel 1 platform. The RUNX3 Illumina GoldenGate reactions did not demonstrate CIMP-specific behavior. One possible explanation for this discrepancy could be that these reactions are designed around the transcription start site of RUNX3 isoform 1, whereas our CIMP-specific RUNX3 MethyLight reaction is designed at the promoter CpG island of the RUNX3 isoform 2 [5]. We saw no apparent difference in DNA methylation between BRAFV600E transfected clones and EVCs at these CIMP-associated CpG sites (Figure 3). Interestingly, we observed that the mean DNA methylation beta-value of the 100 CIMP-specific loci increased as a function of cell passage (Figure 4A and 4B). However, this increase did not correlate with the levels of BRAFV600E expression and was also observed in cells transfected with the control vector (Figure 4B). This general increase in the mean beta-value is specific for CIMP-associated loci, since the mean beta-value from several sets of 100 randomly selected CpG sites did not show a similar trend (Figure 4C and 4D). Therefore, we concluded that, although CIMP-associated CpG islands may be prone to acquire DNA methylation in certain culture conditions, BRAFV600E does not specifically induce CIMP in COLO 320DM cells.
###end p 19
###begin title 20
Illumina GoldenGate DNA methylation profiles of CIMP-associated loci.
###end title 20
###begin p 21
###xml 103 124 103 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 308 313 305 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 416 420 413 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 425 429 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 496 497 493 494 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</bold>
###xml 542 547 539 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
CIMP+ tumors and the CIMP-associated loci in 58 primary tumor samples were defined as described in the Materials and Methods section. Each row corresponds to an individual locus of the 100 locus panel, and the data were sorted by the mean beta-value of each locus over all 58 primary tumor samples. Each BRAFV600E transfected clone and EVC is ordered from left to right in increasing number of passages. Tumors with BRAF and KRAS mutations are indicated by a circle and a triangle, respectively. X: mutation status is not available. Each BRAFV600E transfected clone and EVC is ordered from left to right in increasing number of passages. "p" indicates the DNA methylation profiles of parent untransfected COLO 320DM cells.
###end p 21
###begin title 22
###xml 55 60 55 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Changes in DNA methylation levels over passages in BRAFV600E and EVC stably-transfected clones.
###end title 22
###begin p 23
###xml 25 30 25 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Black lines indicate BRAFV600E expressing clones and gray lines represent empty-vector transfected control clones. Each graphing point represents mean beta-values across indicated CpG sites from the Illumina GoldenGate DNA methylation assay at various passages for each clone. (A) All 1,505 CpG loci from the Illumina GoldenGate assay. (B) Only 100 CIMP-associated loci are profiled. (C) One hundred randomly chosen CpG loci. (D) One hundred non-CIMP loci, which show mean beta-values similar to the 100 CIMP-associated loci.
###end p 23
###begin title 24
###xml 93 98 93 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Identification of Genes That Are Significantly Methylated in Colorectal Tumors Harboring BRAFV600E
###end title 24
###begin p 25
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 298 301 298 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 316 321 316 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 568 569 568 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 591 596 591 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 614 622 614 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s004">Table S3</xref>
###xml 725 730 725 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
We also considered the alternative hypothesis that promoter methylation of specific gene targets provides a favorable setting for the acquisition of BRAF mutation in CIMP+ colorectal cancers. We previously identified the CIMP status and BRAF mutation status of 235 primary colorectal tumor samples [5]. We found BRAFV600E in 33 tumors (14.0%); 31 of these were classified as CIMP+ and only 2 as CIMP-. We performed the Illumina GoldenGate DNA methylation assay on these samples, and identified 60 genes, represented by 89 CpG sites, that are significantly methylated (P<0.001) in the 33 BRAFV600E-positive tumors (Table S3). These genes are candidates for CIMP-specific inactivation, which may closely synergize with the BRAFV600E to promote tumorigenesis.
###end p 25
###begin p 26
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CALCA</italic>
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHA3</italic>
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIT</italic>
###xml 169 175 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC5A8</italic>
###xml 585 590 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CALCA</italic>
###xml 598 603 598 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHA3</italic>
###xml 611 614 611 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIT</italic>
###xml 622 628 622 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC5A8</italic>
To validate the data generated using the GoldenGate DNA methylation platform, we analyzed the DNA methylation status of four CIMP-specific genes (CALCA, EPHA3, KIT, and SLC5A8) on a subset of four CIMP-positive and 16 CIMP-negative tumors on the Illumina Infinium DNA methylation platform. These four genes were selected because both analytical platforms interrogate the DNA methylation status of the identical CpG dinucleotide. We then examined the concordance of DNA methylation at each of these loci between the two platforms, and found a high correlation coefficient in all cases (CALCA: 0.94, EPHA3: 0.95, KIT: 0.95, SLC5A8: 0.86), lending further support to our initial GoldenGate-based DNA methylation screen.
###end p 26
###begin p 27
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP3</italic>
###xml 89 92 89 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCC</italic>
###xml 112 117 112 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Loh1">[25]</xref>
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-KohonenCorish1">[26]</xref>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP6.</italic>
###xml 253 257 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP3</italic>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP6</italic>
###xml 385 389 385 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Kraunz1">[27]</xref>
###xml 428 434 428 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC5A8</italic>
###xml 439 444 439 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TIMP3</italic>
###xml 470 475 470 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 573 577 573 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Xing1">[28]</xref>
###xml 687 692 687 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 713 717 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Loh1">[25]</xref>
###xml 718 722 718 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Xing1">[28]</xref>
We confirmed the recently observed associations between DNA hypermethylation of BMP3 and MCC with CIMP+ and BRAFV600E in colorectal cancer [25], [26]. We also found CIMP-specific DNA hypermethylation of BMP6. The simultaneous epigenetic inactivation of BMP3 and BMP6 was shown to be associated with the activation of the RAS-RAF-MEK-ERK signaling pathway in non-small-cell lung cancer [27]. Moreover, we found an association of SLC5A8 and TIMP3 DNA methylation with BRAFV600E in our colorectal tumor samples, as had been previously reported in papillary thyroid carcinomas [28]. The functional consequence of DNA hypermethylation of such tumor suppressor genes linked with CIMP+ and BRAFV600E remains speculative [25]-[28].
###end p 27
###begin p 28
###xml 46 49 46 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMO</italic>
###xml 140 145 140 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 147 155 147 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s004">Table S3</xref>
###xml 231 234 231 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMO</italic>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Arimura1">[29]</xref>
###xml 365 370 365 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 444 447 444 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMO</italic>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Arimura1">[29]</xref>
###xml 560 563 560 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMO</italic>
###xml 598 603 598 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 605 613 605 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s004">Table S3</xref>
Furthermore, we found that DNA methylation of SMO, a component of Hedgehog (Hh) signaling, was tightly linked to colorectal tumors with BRAFV600E (Table S3). Intriguingly, it has been recently reported that increased expression of SMO contributes to colorectal tumorigenesis [29]. However, Arimura et al. also showed that colorectal cancer cell lines harboring BRAFV600E, including COLO 205, HT-29 and RKO, did not appear to show expression of SMO[29]. Our data indicates that CIMP-specific promoter DNA hypermethylation might be involved in the repression of SMO in colorectal tumors carrying BRAFV600E (Table S3).
###end p 28
###begin title 29
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
Promoter DNA Hypermethylation and Transcriptional Silencing of IGFBP7 in BRAF Mutant CIMP+ Colorectal Cancer
###end title 29
###begin p 30
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 112 117 112 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 119 120 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 136 138 136 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 163 168 163 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Zhu1">[30]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Dankort1">[32]</xref>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Mooi1">[33]</xref>
###xml 370 375 370 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Wajapeyee1">[34]</xref>
###xml 497 503 497 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 588 593 588 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 609 615 609 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 750 755 750 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 781 787 781 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 837 842 837 842 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 861 865 861 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Wajapeyee1">[34]</xref>
We identified the IGFBP7 promoter CpG island as a target for DNA methylation in colorectal tumors harboring BRAFV600E (P value  = 3.1x10-9, Odds ratio  = 12). BRAFV600E has been shown to induce cellular senescence [30]-[32]. Oncogene-induced senescence (OIS) has been recognized as an important tumor suppressor mechanism [33]. The underlying molecular mechanism of BRAFV600E-induced senescence and apoptosis has been elucidated in a recent study [34]. It has been demonstrated that expression of IGFBP7 is both necessary and sufficient to induce senescence and apoptosis mediated by BRAFV600E. Intriguingly, IGFBP7 was shown to be epigenetically silenced by CpG island promoter hypermethylation specifically in primary melanoma samples carrying BRAFV600E, indicating that loss of IGFBP7 expression is critical in the development of BRAFV600E-positive melanoma [34].
###end p 30
###begin p 31
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 234 243 234 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g005">Figure 5A</xref>
###xml 287 293 287 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 339 348 339 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g005">Figure 5B</xref>
###xml 388 393 388 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 419 420 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 436 439 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 451 452 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 468 470 468 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 473 482 473 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g005">Figure 5C</xref>
###xml 534 538 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 788 792 788 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Ogino1">[35]</xref>
###xml 794 798 794 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Shen1">[36]</xref>
###xml 839 845 839 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 871 875 871 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 922 926 922 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 928 929 928 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1022 1028 1022 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1096 1101 1096 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1202 1210 1202 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g006">Figure 6</xref>
###xml 1283 1289 1283 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1372 1378 1372 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1416 1422 1416 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1440 1448 1440 1448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g006">Figure 6</xref>
###xml 1537 1543 1537 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1749 1753 1749 1753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1820 1825 1820 1825 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
The Illumina GoldenGate Methylation Cancer Panel 1 platform contains two IGFBP7 probes (IGFBP7_P297_F and IGFBP7_P371_F) that interrogate the DNA methylation status of two distinct CpG dinucleotides in the IGFBP7 promoter CpG island (Figure 5A). We found that these two CpG sites in the IGFBP7 promoter are cancer-specifically methylated (Figure 5B) and strongly associated with both BRAFV600E (Wilcoxon rank-sum test, P value  = 2.0x10-10) and CIMP (P value  = 3.6x10-9) (Figure 5C). It has been reported that colorectal tumors with KRAS mutations also show DNA hypermethylation at CIMP-associated markers, albeit at a low frequency, and have high levels of DNA methylation of genes that undergo age-associated DNA hypermethylation. These tumors have been described as CIMP-low or CIMP2 [35], [36]. We did not find an association between IGFBP7 DNA hypermethylation and KRAS mutations when we excluded tumors with mutant BRAF (P value  = 0.85). In agreement with these observations, we found that DNA hypermethylation of IGFBP7 is mostly present in colorectal cancer cell lines which harbor BRAFV600E and show frequent DNA methylation of the five-gene CIMP-specific marker panel previously described (Figure 6). Real-time RT-PCR analysis of colorectal cancer cell lines showed that IGFBP7 mRNA expression was inversely related to DNA hypermethylation, as cell lines with IGFBP7 hypermethylation showed little or no IGFBP7 gene expression (Figure 6). Among the CIMP- cells we examined, only COLO 320DM showed DNA hypermethylation of the IGFBP7 CpG island promoter with minimal level of expression. In retrospect, this unique characteristic of COLO 320DM cells compared to the other CIMP- cell lines might have enabled these cells to tolerate mutant BRAF overexpression, and may explain our difficulties in obtaining BRAFV600E expressing clones in other colorectal cancer cell line such as Caco-2.
###end p 31
###begin title 32
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
IGFBP7 promoter DNA methylation in primary colorectal cancers.
###end title 32
###begin p 33
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 444 448 441 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 483 487 480 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 560 566 557 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 647 651 644 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 707 713 704 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1011 1032 1005 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 609 614 <span type="species:ncbi:9606">human</span>
(A) Genomic map of IGFBP7 promoter-associated CpG island, transcription start site (TSS) and exon 1 based on the UCSC genome browser (March 2006 assembly). The location of CpG sites interrogated by the Illumina GoldenGate DNA methylation assay is indicated by vertical arrows. (B) DNA methylation levels of the two CpG dinucelotides in the IGFBP7 promoter CpG island. beta-values of each CpG site in 10 tumors (five CIMP- tumors with wild-type BRAF and five CIMP+ tumors with mutant BRAF, black bars) and adjacent non-tumor tissues (gray bars) are listed. (C) IGFBP7 promoter DNA methylation box plots of 235 human colorectal tumors stratified by BRAF mutation status (left) and CIMP+ status (right) at the IGFBP7 P371 locus. In the box plots, the ends of the box are the 25th and 75th quartiles. The line within the box identifies the median beta-value. The whiskers above and below the box extend to at most 1.5 times the IQR. The CIMP status of each colorectal tumor sample is determined as described in the Materials and Methods section.
###end p 33
###begin title 34
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
Analysis of DNA methylation and mRNA expression of IGFBP7 in colorectal cancer cell lines.
###end title 34
###begin p 35
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCNA</italic>
###xml 295 299 295 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 319 327 319 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g001">Figure 1</xref>
Quantitative real-time RT-PCR analysis of IGFBP7 expression. IGFBP7 expression levels are presented relative to PCNA expression. The error bars indicate the standard deviation of technical triplicate measurements. The number of methylated loci among the five CIMP markers and mutation status of BRAF and KRAS listed in Figure 1 are provided.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 201 204 201 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Issa1">[3]</xref>
###xml 206 210 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Schuebel1">[37]</xref>
###xml 300 303 300 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Issa1">[3]</xref>
###xml 305 308 305 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 310 313 310 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Samowitz1">[7]</xref>
###xml 315 318 315 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Kambara1">[8]</xref>
###xml 398 403 398 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 403 406 403 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 458 462 458 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Schuebel1">[37]</xref>
CIMP in colorectal cancer provides a unique opportunity to study molecular mechanisms that lead to epigenetic changes in cancer and the contributions of these changes in the development of the disease [3], [37]. The distinct features found in CIMP are important clues in understanding this phenotype [3], [5], [7], [8]. Particularly striking is the extremely tight association between CIMP and BRAFV600E[5]. Mechanisms linking epigenetic (CIMP) and genetic (BRAF mutation) events and the temporal sequence in which these two events take place have attracted interest [37].
###end p 37
###begin p 38
###xml 136 141 136 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 206 211 206 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 265 270 265 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 442 447 442 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 550 555 550 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 645 649 645 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 723 727 723 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Rosenberg1">[10]</xref>
###xml 729 733 729 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Beach1">[38]</xref>
###xml 735 739 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-OBrien2">[39]</xref>
###xml 899 904 899 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1034 1038 1034 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1168 1173 1168 1173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1206 1211 1206 1211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1331 1336 1331 1336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1412 1418 1412 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1438 1443 1438 1443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
In this study, by using the high-throughput Illumina GoldenGate DNA methylation platform, we investigated the link between CIMP and BRAFV600E in colorectal cancer. We first tested whether expression of BRAFV600E causes DNA hypermethylation by stably expressing BRAFV600E in the CIMP-negative, BRAF wild-type COLO 320DM colorectal cancer cell line. We have examined DNA methylation changes in 100 CIMP-associated CpG sites, and found that BRAFV600E is not sufficient to induce DNA hypermethylation at these sites. One caveat of our system is that BRAFV600E could play a role in inducing DNA methylation only early in colorectal tumorigenesis, as BRAF mutations have been described at the earliest stage of tumor development [10], [38], [39]. It is possible that a unique set of genetic and/or epigenetic changes that occurred in COLO 320DM cells might have created an unfavorable environment for BRAFV600E to induce DNA hypermethylation. Experiments similar to those described above using Caco-2 cells, which also show CIMP- and carry BRAF-wild type, were not successful. We were not able to obtain any stably transfected clones that exhibited detectable levels of BRAFV600E (data not shown). Sustained BRAFV600E expression might be incompatible with Caco-2 cell proliferation due to cellular senescence or apoptosis induced by BRAFV600E. It is noteworthy that our RT-PCR analysis showed the robust expression of IGFBP7, a mediator of BRAFV600E-induced senescence or apoptosis, in Caco-2 cells in contrast to COLO 320DM cells.
###end p 38
###begin p 39
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 153 156 153 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 233 238 233 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Minoo2">[40]</xref>
###xml 324 328 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 387 392 387 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 444 448 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 486 491 486 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 527 531 527 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 637 641 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 730 733 730 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-OBrien1">[6]</xref>
###xml 735 739 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Rosenberg1">[10]</xref>
###xml 741 745 741 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Velho1">[41]</xref>
###xml 769 773 769 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 883 889 883 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 928 934 928 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1038 1043 1038 1043 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1087 1091 1087 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Minoo2">[40]</xref>
Previously, we described CIMP-associated methylation of MLH1 as the underlying basis for mismatch repair deficiency (MSI+) in sporadic colorectal cancer [5]. Minoo et al. reported MLH1 DNA methylation upon stable transfection of BRAFV600E into the NCM460 cell line [40]. In our system, we did not detect such an increase in MLH1 DNA methylation (data not shown). Moreover, of the 33 BRAFV600E primary tumors we examined only 42% (14/33) showed MLH1 DNA hypermethylation. Therefore, BRAFV600E may affect DNA hypermethylation of MLH1 but only in certain circumstances. Interestingly, in the proposed serrated pathway to CIMP+ tumors, both BRAF mutations and CIMP+ have been observed in early precursor lesions, whereas MSI+ has not [6], [10], [41]. Thus, inactivation of MLH1 might occur at a later stage of tumor development. Minoo and colleagues observed the DNA hypermethylation of CDKN2A and 15 other CIMP-associated markers (IGFBP7 was not examined) in parent NCM460 cells, which limited their ability to study further the role of BRAFV600E inducing CIMP in their experimental system [40].
###end p 39
###begin p 40
###xml 300 304 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Muthuswami1">[42]</xref>
Intriguingly, we observed that the overall DNA methylation level of the CIMP-specific loci in our stably transfected cells increases as a function of cell passage. It is interesting to note that a selection drug in cultured cells has been described to result in changes in global chromatin structure [42], and a similar process may be associated with our observations here.
###end p 40
###begin p 41
###xml 146 156 146 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g002">Figures 2B</xref>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g003">3</xref>
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 317 318 313 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 355 356 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 461 465 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Bibikova2">[16]</xref>
###xml 575 585 567 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g002">Figures 2B</xref>
###xml 590 591 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g003">3</xref>
In addition, we found relatively large inter-clonal (among different clones) variation in DNA methylation levels in our transfection experiments (Figures 2B and 3), with an average R2 correlation calculated based on four EVCs of 0.88+/-0.01 (+/- s.d.). Our average intra-clonal (within clones at different passages) R2 correlation is 0.97+/-0.01 and the R2 correlation between technical replicates in Illumina GoldenGate DNA methylation analysis is 0.98+/-0.02 [16]. Consequently, we found some large differences in DNA methylation at several loci even among control clones (Figures 2B and 3). This emphasizes the importance of using multiple clones for this type of studies.
###end p 41
###begin p 42
###xml 59 64 59 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 144 149 144 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 283 288 283 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 419 425 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 463 468 463 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Wajapeyee1">[34]</xref>
###xml 521 526 521 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 608 612 608 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Zhu1">[30]</xref>
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Michaloglou1">[31]</xref>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Dankort1">[32]</xref>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Mooi1">[33]</xref>
###xml 769 774 769 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 873 877 873 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Mooi1">[33]</xref>
###xml 916 921 916 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1011 1017 1011 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1039 1044 1039 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1166 1172 1166 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1341 1347 1341 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1363 1368 1363 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1427 1433 1427 1433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 1511 1516 1511 1516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1516 1520 1516 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Wajapeyee1">[34]</xref>
###xml 596 601 <span type="species:ncbi:9606">human</span>
###xml 631 636 <span type="species:ncbi:10090">mouse</span>
###xml 1067 1072 <span type="species:ncbi:9606">human</span>
###xml 1255 1260 <span type="species:ncbi:9606">human</span>
Alternatively, the strong association between CIMP and BRAFV600E might arise if CIMP specifically provides a favorable cellular context for BRAFV600E to promote tumorigenesis. In the second set of experiments, we determined genes whose DNA hypermethylation was tightly linked to BRAFV600E and CIMP+ in colorectal cancer. Intriguingly, we observed CIMP-dependent DNA hypermethylation and transcriptional inactivation of IGFBP7, which has been shown to mediate BRAFV600E-induced cellular senescence and apoptosis [34]. BRAFV600E has been shown to induce cellular senescence in cultured and primary human cells [30], [31], as well as mouse model [32]. Oncogene-induced senescence (OIS) has been recognized as an important tumor suppressor mechanism [33]. In order for BRAFV600E to promote its oncogenic effects, additional cooperative events are required to bypass senescence [33]. Recently, the molecular basis of BRAFV600E-induced senescence and apoptosis has been studied in detail. Wajapeyee et al. identified IGFBP7 as a mediator of BRAFV600E-induced senescence in human primary fibroblasts using a genome-wide shRNA screen. Their subsequent findings suggest that IGFBP7 expression is both necessary and sufficient to induce senescence and apoptosis in human primary melanocytes and melanoma, respectively. Moreover, they observed loss of IGFBP7 in primary BRAFV600E-positive melanoma samples and concluded that silencing of IGFBP7 expression is a critical step in the development of a melanoma harboring BRAFV600E[34].
###end p 42
###begin p 43
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 364 368 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Lin1">[43]</xref>
###xml 400 404 400 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 511 517 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 616 621 616 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 667 673 667 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 806 811 806 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 856 862 856 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 944 949 944 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 434 439 <span type="species:ncbi:9606">human</span>
Promoter-associated CpG island DNA hypermethylation of IGFBP7 has been reported in human colorectal cancer cell lines as well. The DNA methylation inhibitor 5-aza-2'-deoxycytidine has been shown to restore IGFBP7 expression in colorectal cancer cell lines, indicating that the DNA hypermethylation plays a major role in silencing of this gene in colorectal cancer [43]. However, its association with BRAF mutation and CIMP+ status in human colorectal cancers has not been explored. In this study, we found that IGFBP7 DNA hypermethylation is tumor-specific and tightly associated with colorectal tumors carrying BRAFV600E and exhibiting CIMP. Moreover, we found that IGFBP7 DNA hypermethylation is associated with loss of expression in CIMP+ colorectal cancer cell lines. CIMP-specific inactivation of BRAFV600E-induced senescence and apoptosis pathway by IGFBP7 DNA hypermethylation might create a favorable context for the acquisition of BRAFV600E in CIMP+ colorectal cancer.
###end p 43
###begin p 44
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 282 288 282 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Lin1">[43]</xref>
###xml 482 486 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Cichowski1">[44]</xref>
Importantly, IGFBP7 DNA hypermethylation was not observed in all of the BRAF mutant colorectal tumors. Lin et al. examined the DNA sequence of the promoter and exonic regions of IGFBP7 in ten colorectal cancer cell lines. They did not find mutations associated with inactivation of IGFBP7 in their cell lines [43]. However, an increasing number of genes have recently been reported to be involved in OIS, and cooperation of multiple different signals appears to be critical for OIS [44]. It is therefore possible that CIMP-associated DNA hypermethylation events may impair OIS by affecting other components of the OIS signaling pathway in colorectal cancer.
###end p 44
###begin p 45
###xml 158 166 158 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s004">Table S3</xref>
###xml 313 317 313 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP3</italic>
###xml 322 326 322 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP6</italic>
###xml 412 417 412 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Loh1">[25]</xref>
###xml 564 568 564 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP3</italic>
###xml 573 577 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BMP6</italic>
###xml 701 705 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Kraunz1">[27]</xref>
###xml 761 771 761 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHA3, KIT</italic>
###xml 777 781 777 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLT1</italic>
###xml 832 840 832 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s004">Table S3</xref>
###xml 1009 1013 1009 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Bardelli1">[45]</xref>
###xml 1014 1018 1014 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Wood1">[50]</xref>
###xml 1252 1255 1252 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMO</italic>
###xml 1260 1264 1260 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HHIP</italic>
###xml 1315 1320 1315 1320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1322 1330 1322 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s004">Table S3</xref>
###xml 1333 1336 1333 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMO</italic>
###xml 1341 1345 1341 1345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HHIP</italic>
###xml 1470 1473 1470 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMO</italic>
###xml 1617 1621 1617 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Arimura1">[29]</xref>
###xml 1667 1670 1667 1670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMO</italic>
###xml 1730 1735 1730 1735 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1735 1739 1735 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Arimura1">[29]</xref>
###xml 1942 1950 1942 1950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008357.s004">Table S3</xref>
###xml 1572 1577 <span type="species:ncbi:10090">mouse</span>
Additional genes that showed CIMP-specific DNA hypermethylation include those that mediate various signaling pathways implicated in colorectal tumorigenesis (Table S3). The functional consequence of CIMP-specific DNA hypermethylation of such genes will be the subject of future investigations. We found that both BMP3 and BMP6 are targeted for CIMP-specific DNA hypermethylation and are strongly linked with BRAFV600E. Disruption of the BMP signaling pathway has been proposed to play a role in colorectal tumorigenesis [25]. Concurrent epigenetic inactivation of BMP3 and BMP6 was shown to be associated with the hyperactivation of the RAS-RAF-MEK-ERK signaling pathway in non-small-cell lung cancer [27]. Furthermore, receptor tyrosine kinases (RTKs) such as EPHA3, KIT, and FLT1 also showed CIMP-associated DNA hypermethylation (Table S3). Somatic mutations or overexpression of these genes has been implicated in colorectal tumorigenesis, which may involve the activation of the RAS-RAF-MEK-ERK signaling [45]-[50]. The potential inactivation of these genes in CIMP may lead to the development of tumors dependent on oncogenic BRAF-driven hyperactivation of the RAS-RAF-MEK-ERK signaling pathway. Furthermore, we also found that DNA methylation of SMO and HHIP were closely linked to colorectal tumors with BRAFV600E (Table S3). SMO and HHIP are involved in the regulation of the Hedgehog (Hh) signaling pathway. It has been demonstrated that elevated expression of SMO might contribute to colorectal tumorigenesis through activation of the Wnt signaling pathway in a mouse model and colorectal cancer cell lines [29]. Notably, it appeared that the expression of SMO was silenced in colorectal cancer cell lines harboring BRAFV600E[29]. Our data in primary colorectal tumors indicate that the CIMP-specific promoter DNA hypermethylation may result in a different effect of the Hedgehog (Hh) signaling pathway on colorectal tumorigenesis (Table S3).
###end p 45
###begin p 46
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP7</italic>
###xml 314 319 314 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 384 389 384 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Our data will be a useful resource for future investigations toward understanding CIMP and the role of aberrant DNA hypermethylation in colorectal tumorigenesis. The inactivation of a senescence pathway by IGFBP7 DNA hypermethylation in CIMP+ tumors may provide a permissive environment for the acquisition of BRAFV600E, thus providing a possible explanation for the link between BRAFV600E and CIMP in colorectal cancer.
###end p 46
###begin title 47
Materials and Methods
###end title 47
###begin title 48
Ethics Statement
###end title 48
###begin p 49
###xml 466 469 466 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 183 188 <span type="species:ncbi:9606">Human</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
This study was conducted according to the principles expressed in the Declaration of Helsinki. The study was approved by the Institutional Review Board of the Royal Brisbane Hospital Human Research Ethics Committee, the Bancroft Centre Ethics Committee and the University of Southern California. All patients provided written informed consent for the collection of samples and subsequent analysis. DNA from these patients was also analyzed in a previous publication [5].
###end p 49
###begin title 50
Cell Culture and Genomic DNA Isolation
###end title 50
###begin p 51
###xml 218 223 218 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 677 681 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Laird1">[51]</xref>
Colorectal cancer cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). COLO 320DM cells were grown in DMEM supplemented with 10% FBS, 1 mM glutamine. An empty vector and an HA-tagged BRAFV600E cDNA clone (pMEV-HA, pMEV-BRAF-V599E, Biomyx Technology, San Diego, CA, USA) were transfected into COLO 320DM cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). G418 (Sigma-Aldrich, St. Louis, MO, USA) (1 mg/ml) was added 48 hours after transfection and resistant clones were randomly isolated and expanded. Stably expressing clones were maintained in 500 microg/ml of G418. Genomic DNA from each clone was isolated as previously described [51].
###end p 51
###begin title 52
MethyLight Analysis of Five CIMP-Specific Markers in Colorectal Cancer Cell Lines
###end title 52
###begin p 53
###xml 110 113 110 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 115 119 115 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger2">[52]</xref>
###xml 207 210 207 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 329 332 329 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
Genomic DNA was treated with sodium bisulfite and subsequently analyzed by MethyLight as previously described [5], [52]. The primer and probe sequences for the MethyLight reactions were described previously [5]. The results of MethyLight analyses were scored as PMR (Percent of Methylated Reference) values as previously defined [5].
###end p 53
###begin title 54
Mutation Analysis and MSI Status of Colorectal Cancer Cell Lines
###end title 54
###begin p 55
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Davies1">[13]</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Suter1">[53]</xref>
Primer sequences and PCR conditions for direct sequencing of BRAF at codon 600 in exon 15 and at codons 12 and 13 of KRAS in exon 2 were reported previously [13]. The MSI status of each cell line was based on the Sanger Institute Cancer Genome Project () and based on a previous study [53].
###end p 55
###begin title 56
Western Blot Analysis
###end title 56
###begin p 57
###xml 437 442 437 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 607 618 <span type="species:ncbi:3704">horseradish</span>
Whole cell extracts were prepared from each resistant clone at the first passage using CelLytic M Cell Lysis Reagent (Sigma-Aldrich). Equal amounts of protein from whole cell extracts were separated on gradient (4-20%) polyacrylamide gels (Invitrogen) and then transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). Blots were probed with the anti-HA antibodies (Roche, Indianapolis, IN, USA) for HA-BRAFV600E, anti-phospho-ERK1/2 (Cell Signaling, Beverly, MA, USA), and anti-ERK1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by incubation with species specific horseradish peroxidase-conjugated secondary antibodies (Santa Cruz). Proteins were visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA).
###end p 57
###begin title 58
Primary Colorectal Tissue Samples
###end title 58
###begin p 59
###xml 95 98 95 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 219 222 219 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 380 383 380 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 429 433 429 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 482 485 482 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 487 491 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 506 510 506 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 616 620 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 676 680 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 695 699 695 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 734 737 734 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
Primary colorectal tissue samples were collected and DNA was extracted as previously described [5]. A 58 sample set included five CIMP+ tumors, five CIMP- tumors and 48 randomly selected tumors, as indicated previously [5]. A 235 sample set included the same 48 randomly selected samples described above along with an additional 187 randomly collected tumors described previously [5]. CIMP status and mutation status of BRAF and KRAS for each tumor sample was previously determined [5]. BRAF mutations and KRAS mutations were found in 15% (33/235) and 33% (74/221) of the colorectal tumor samples, respectively. The KRAS mutation status of 14 tumor samples was not available. BRAF mutations and KRAS mutations were mutually exclusive [5].
###end p 59
###begin title 60
DNA Methylation Analysis by the Illumina GoldenGate and Infinium DNA Methylation Platforms
###end title 60
###begin p 61
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Bibikova2">[16]</xref>
Genomic DNA was bisulfite converted using the EZ-96 DNA Methylation Kit (ZYMO Research, Orange, CA, USA) according to manufacturer's protocol. Illumina GoldenGate DNA methylation analyses were performed as previously described [16] at the USC Epigenome Center Core Facility. Target sequences for the assay and detailed information on each interrogated CpG site and the associated gene on the "GoldenGate Methylation Cancer Panel 1" are described at . The Illumina Infinium DNA methylation assay was performed following manufacturer's specifications. Detailed information on each interrogated CpG site and the associated gene on the Infinium BeadArray is available at .
###end p 61
###begin title 62
Identification of CIMP-Associated DNA Methylation Markers Using 58 Primary Colorectal Tumor Samples
###end title 62
###begin p 63
###xml 75 83 75 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008357-g003">Figure 3</xref>
###xml 369 370 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 524 525 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 575 579 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Bardelli1">[45]</xref>
###xml 635 639 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Bibikova2">[16]</xref>
For the hierarchical cluster analysis on 58 primary tumor samples shown in Figure 3, we used the beta-values obtained from 1,421 reactions (84 X-linked reactions were omitted). We used Euclidian distance and Ward's linkage method to perform the clustering (JMP 6.0 software, SAS Institute, Cary, NC, USA). In order to identify CIMP-associated CpG sites, we performed a t-test on the difference in the beta-value between the CIMP-positive group (11 tumors) and CIMP-negative group (47 tumors). We selected 100 CpG sites with P<0.001 after a correction for multiple-comparison [45] and mean |Deltabeta|>0.17, the estimated error in beta [16].
###end p 63
###begin title 64
Quantitative Real-Time RT-PCR
###end title 64
###begin p 65
###xml 428 432 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCNA</italic>
Total RNA from colorectal cancer cell lines were isolated using RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany). Reverse transcription reaction was performed using the SuperScript(R) III First-Strand Synthesis kit (Invitrogen). Quantitative real-time PCR was performed with primers and probe purchased from Applied Biosystems (Assay ID Hs00266026_m1) (Foster City, CA, USA). The raw expression values were normalized to those of PCNA.
###end p 65
###begin title 66
Supporting Information
###end title 66
###begin p 67
Raw beta-values obtained from the Illumina GoldenGate DNA methylation assay on 58 primary colorectal tumor samples. Samples are labeled with internal IDs.
###end p 67
###begin p 68
(1.72 MB XLS)
###end p 68
###begin p 69
Click here for additional data file.
###end p 69
###begin p 70
Characteristics of the 58 Primary colorectal tumor samples.
###end p 70
###begin p 71
(0.02 MB XLS)
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin p 73
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
One hundred (100) CpG sites that have significantly higher levels of DNA methylation in CIMP-positive versus CIMP-negative tumors. P values and difference in mean beta-values between CIMP-positive tumors and CIMP-negative tumors are also included.
###end p 73
###begin p 74
(0.02 MB XLS)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
###xml 104 109 104 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 286 289 286 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008357-Weisenberger1">[5]</xref>
###xml 617 618 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 744 745 738 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The Illumina GoldenGate DNA methylation loci specifically methylated in colorectal tumors harboring BRAFV600E. We performed the Illumina GoldenGate DNA methylation assay on 235 primary colorectal tumor samples, whose CIMP status and BRAF mutation status have been determined previously [5]. We dichotomized the DNA methylation beta-value (methylated or unmethylated) for each locus. The dichotomization threshold was chosen for each locus using the mean beta-value + 3SD (standard deviations) from ten normal mucosal samples. The table lists 89 Illumina GoldenGate DNA methylation targets (of 60 genes) selected with P<0.001 (Fisher's exact test) after Bonferroni correction for multiple comparisons. Target CpG sites are sorted based on their P values.
###end p 76
###begin p 77
(0.03 MB XLS)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin title 79
References
###end title 79
###begin article-title 80
The epigenomics of cancer.
###end article-title 80
###begin article-title 81
CpG island methylator phenotype in colorectal cancer.
###end article-title 81
###begin article-title 82
CpG island methylator phenotype in cancer.
###end article-title 82
###begin article-title 83
Genetics supersedes epigenetics in colon cancer phenotype.
###end article-title 83
###begin article-title 84
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.
###end article-title 84
###begin article-title 85
Hyperplastic and serrated polyps of the colorectum.
###end article-title 85
###begin article-title 86
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer.
###end article-title 86
###begin article-title 87
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.
###end article-title 87
###begin article-title 88
Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis.
###end article-title 88
###begin article-title 89
###xml 119 125 <span type="species:ncbi:9606">humans</span>
Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans.
###end article-title 89
###begin article-title 90
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status.
###end article-title 90
###begin article-title 91
###xml 30 35 <span type="species:ncbi:9606">human</span>
Guilty as charged: B-RAF is a human oncogene.
###end article-title 91
###begin article-title 92
###xml 30 35 <span type="species:ncbi:9606">human</span>
Mutations of the BRAF gene in human cancer.
###end article-title 92
###begin article-title 93
Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question.
###end article-title 93
###begin article-title 94
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human embryonic stem cells have a unique epigenetic signature.
###end article-title 94
###begin article-title 95
High-throughput DNA methylation profiling using universal bead arrays.
###end article-title 95
###begin article-title 96
###xml 38 43 <span type="species:ncbi:9606">human</span>
DNA methylation signatures within the human brain.
###end article-title 96
###begin article-title 97
Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions.
###end article-title 97
###begin article-title 98
###xml 47 52 <span type="species:ncbi:9606">human</span>
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
###end article-title 98
###begin article-title 99
A microarray-based DNA methylation study of glioblastoma multiforme.
###end article-title 99
###begin article-title 100
GoldenGate(R) Assay for DNA Methylation Profiling.
###end article-title 100
###begin article-title 101
###xml 45 50 <span type="species:ncbi:9606">human</span>
Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns.
###end article-title 101
###begin article-title 102
Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context.
###end article-title 102
###begin article-title 103
###xml 51 59 <span type="species:ncbi:9606">children</span>
DNA methylation and gene expression differences in children conceived in vitro or in vivo.
###end article-title 103
###begin article-title 104
Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development.
###end article-title 104
###begin article-title 105
Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer.
###end article-title 105
###begin article-title 106
Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer.
###end article-title 106
###begin article-title 107
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
###end article-title 107
###begin article-title 108
Reduced level of smoothened suppresses intestinal tumorigenesis by down-regulation of Wnt signaling.
###end article-title 108
###begin article-title 109
###xml 14 19 <span type="species:ncbi:9606">human</span>
Senescence of human fibroblasts induced by oncogenic Raf.
###end article-title 109
###begin article-title 110
###xml 57 62 <span type="species:ncbi:9606">human</span>
BRAFE600-associated senescence-like cell cycle arrest of human naevi.
###end article-title 110
###begin article-title 111
###xml 6 11 <span type="species:ncbi:10090">mouse</span>
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
###end article-title 111
###begin article-title 112
Oncogene-induced cell senescence-halting on the road to cancer.
###end article-title 112
###begin article-title 113
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.
###end article-title 113
###begin article-title 114
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
###end article-title 114
###begin article-title 115
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer.
###end article-title 115
###begin article-title 116
CIMPle origin for promoter hypermethylation in colorectal cancer?
###end article-title 116
###begin article-title 117
BRAF mutations in aberrant crypt foci and hyperplastic polyposis.
###end article-title 117
###begin article-title 118
Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.
###end article-title 118
###begin article-title 119
Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.
###end article-title 119
###begin article-title 120
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
###end article-title 120
###begin article-title 121
Phosphoaminoglycosides inhibit SWI2/SNF2 family DNA-dependent molecular motor domains.
###end article-title 121
###begin article-title 122
Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression.
###end article-title 122
###begin article-title 123
Unexpected pieces to the senescence puzzle.
###end article-title 123
###begin article-title 124
Mutational analysis of the tyrosine kinome in colorectal cancers.
###end article-title 124
###begin article-title 125
Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids.
###end article-title 125
###begin article-title 126
Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins.
###end article-title 126
###begin article-title 127
Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.
###end article-title 127
###begin article-title 128
KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes.
###end article-title 128
###begin article-title 129
###xml 26 31 <span type="species:ncbi:9606">human</span>
The genomic landscapes of human breast and colorectal cancers.
###end article-title 129
###begin article-title 130
Simplified mammalian DNA isolation procedure.
###end article-title 130
###begin article-title 131
Analysis of repetitive element DNA methylation by MethyLight.
###end article-title 131
###begin article-title 132
CpG island methylation is a common finding in colorectal cancer cell lines.
###end article-title 132
###begin p 133
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Peter Laird is a consultant for Epigenomics AG and for Celgene Corporation. The other authors disclosed no potential competing interest. This work was not supported by either Epigenomics AG or Celgene Corporation. These companies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 133
###begin p 134
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: National Institutes of Health (NIH) grants R01 CA118699-02 (P.W. Laird), R01 CA075090-09 (P.W. Laird). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 134

